期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗凝溶栓药物治疗血管疾病中出血风险评估及处理 被引量：10

The bleeding risk assessment and treatment strategies of anticoagulant and thrombolytic drugs
原文传递
导出
摘要 抗凝和溶栓治疗在血管外科中被广泛应用于防治血栓(栓塞)形成和(或)复发,然而,这些药物所带来的出血风险不容忽视。准确评估病人的出血风险,选择合理有效的药物,定期规律的监测,及时快速的处理是在使用抗凝溶栓药物过程中所要遵守的操作规程。 Anticoagulant and thrombolytic therapy have been widely applied in the treatment or prevention for thrombosis （embolism） and/or recurrence in vascular surgery. However, the risk of bleeding caused by the drugs could not be ignored. The bleeding risk assessment and treatment strategies of anticoagulant and thrombolytic drugs should be implemented.
作者 蒋米尔 刘光
机构地区 上海交通大学医学院附属第九人民医院血管外科上海交通大学医学院血管病诊治中心
出处 《中国实用外科杂志》 CSCD 北大核心 2011年第12期1095-1098,共4页 Chinese Journal of Practical Surgery
关键词 抗凝药 溶栓药 出血 风险评估 处理对策 anticoagulant drugs thrombolytic drugs bleeding risk assessment treatment strategy
分类号 R6 [医药卫生—外科学]
  • 相关文献

参考文献9

  • 1Schulman S, Angeras U, Bergqvist D, et al.Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients [J]. J Thromb Haemost,2010,8(1): 202-204.
  • 2Schulman S, Kearon C. Subcommittee on Control of Anticoagula- tion of the Scientific and Standardization Committee of the Inter- national Society on Thrombosis and Haemostasis.Definition of major bleeding in clinical investigations of antihemostatic me- dicinal products in non-surgical patients [J]. J Thromb Haemost, 2005.3(4):692-694.
  • 3Aspinall SL, DeSanzo BE, Trilli LE, et al. Bleeding Risk Index in an anticoagulation clinic. Assessment by indication and impli- cations for care[J]. J Gen Intern Med,2005,20(11): 1008-1013.
  • 4Shireman TI, Mahnken JD, Howard PA, et al. Development of a contemporary bleeding risk model for elderly warfarin recipients [ J]. Chest,2006,130(5):1390-1396.
  • 5Ebell MH.Predicting the risk of bleeding in patients taking war- farin[J]. Am Fam Physician, 2010,81(6):780.
  • 6Perler B. Thrombolytic therapies: the current state of affairs [J]. J Endovasc Ther,2005,12(2):224-232.
  • 7Schulman S, Beyth RJ, Kearon C, et al.Hemorrhagic complica- tions of anticoagulant and thrombolytic treatment: American Col- lege of Chest Physicians Evidence-Based Clinical Practice Guidelines(8th Edition)[J ].Chest,2008,133(suppl 6):257-298.
  • 8蔡晓红,王鸿利,王学锋.抗凝与溶栓治疗的实验室监测及其应用评价[J].国际检验医学杂志,2006,27(1):27-29. 被引量：7
  • 9王鸿利.抗凝药物和溶栓药物的临床应用和实验监测[J].内科急危重症杂志,2001,7(4):184-189. 被引量：4

二级参考文献15

  • 1Anand SS,Yusuf S,Pogue J,et al.Relationship of activated par tial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin.Circulation,2003,107(23):2884-2888.
  • 2Moliterno DJ,Hermiller JB,Kereiakes DJ,et al.A novel point-ofcare enoxaparin monitor for use during percutaneous coronary intervention.Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study.J Am Coll Cardiol,2003,42(6):1132-1139.
  • 3Marmur JD,Anand SX,Bagga RS,et al.The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration.J Am Coll Cardiol,2003,41(3):394-402.
  • 4Murray ET,Fitzmaurice DA,McCahon D.Point of care testing for INR monitoring:where are we now? Br J Haematol,2004,127(4):373-378.
  • 5LaCapra S,Arkel YS,Ku DH,et al.The use of thrombus precursor protein,D-dimer,prothrombin fragment 1.2,and thrombin an tithrombin in the exclusion of proximal deep vein thrombosis and pulmonary embolism.Blood Coagul Fibrinolysis,2000,11 (4):371-377.
  • 6Nowak G.Clinical monitoring of hirudin and direct thrombin inhibitors.Semin Thromb Hemost,2001,27(5):537-541.
  • 7Iqbal O,Tobu M,Aziz S,et al.Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin induced thrombocytopenia undergoing off-pump coronary artery revascularization.J Card Surg,2005,20(1):42-51.
  • 8Fenyvesi T,Jorg I,Harenberg J.Monitoring of anticoagulant effects of direct thrombin inhibitors.Semin Thromb Hemost,2002,28(4):361 368.
  • 9Lowe GD.How to search for the role and prevalence of defective fi brinolytic states as triggers of myocardialinfarction? The haemostasis epidemiologist's view.Ital Heart J,2001,2(9):656-657.
  • 10Scharfstein JS,Abendschein DR,Eisenberg PR,et al.Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction.TIMI-5 Investigators.Thrombolysis in Myocardial Infarction.Am J Cardiol,1996,78(5):503-510.

共引文献9

同被引文献85

  • 1郭松林,袁良喜,周建,景在平,包俊敏.急性下肢深静脉血栓置管溶栓治疗的早、中期疗效分析[J].中国血管外科杂志（电子版）,2013,5(2):86-89. 被引量：17
  • 2王深明,武日东.规范下肢深静脉血栓形成的治疗[J].中国血管外科杂志（电子版）,2014,6(1):1-3. 被引量：20
  • 3张晓蓉,何文,唐华,梁晓宁,徐利群,戴可定,高堃.小腿静脉血栓的影像学诊断[J].中国医学影像技术,2004,20(7):1064-1067. 被引量：55
  • 4张益民（摘）,李幼姬（校）.低分子肝素与严重肾衰竭患者的大出血[J].中国中西医结合肾病杂志,2006,7(8):405-405. 被引量：6
  • 5Canale S T,Beaty J H.坎贝尔骨科手术学[M].王岩译.北京:人民出版社,2009.
  • 6汪忠镐 张建 谷涌泉.实用血管外科与血管介入治疗学[M].北京:人民军医出版社,2004.337-339.
  • 7Kahn SR. The post-thrombotic syndrome: progress and pitfalls [ J ] British journal of haematology, 2006,13 (4) :357 - 365.
  • 8Mantoni M. Ultrasound of limb veins[ J ]. Eur Radial, 2001,11 (9) 1557 - 1562.
  • 9Baarslag HJ, Van Beck EJR , Reekers JA. Magnetic resonance venogra- phy in consecutive patients with suspected deep vein thrombosis of the upper extremity: initial experience [ J]. Acta Radial, 2004,45 (1) :38 -43.
  • 10卓大洪.中国康复医学[M].北京:华夏出版社,2003:385.

引证文献10

二级引证文献51

中国实用外科杂志
2011年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部